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ABSTRACT 
Objective: To conduct a systematic review and meta-analysis investigating effects of MedDiet 
on blood pressure in randomised controlled trials (RCTs) and associations of MedDiet with 
risk of hypertension in observational studies. 
Methods: PubMed, The Cochrane Library and EBSCOhost were searched from inception until 
January 2020 for studies that met the following criteria: 1) participants aged ≥18 years, 2) RCTs 
investigating effects of a MedDiet versus control on BP, 3) Observational studies exploring 
associations between MedDiet adherence and risk of hypertension.  Random-effects meta-
analyses were conducted. Meta-regression and subgroup analyses were performed for RCTs to 
identify potential effect moderators. 
Results: Nineteen RCTs reporting data on 4137 participants and 16 observational studies 
reporting data on 59,001 participants were included in the meta-analysis.  MedDiet 
interventions reduced systolic and diastolic BP by a mean -1.4 mmHg (95% CI: -2.40 to -0.39 
mmHg, p=0.007, I2=53.5%, Q=44.7, τ2=1.65, df=19) and -1.5 mmHg (95% CI: -2.74 to -0.32 
mmHg, p=0.013, I2=71.5%, Q=51.6, τ2=4.72, df=19) versus control, respectively. Meta-
regression revealed that longer study duration and higher baseline systolic BP was associated 
with a greater decrease in BP, in response to a MedDiet (p<0.05).  In observational studies, 
odds of developing hypertension were 13% lower with higher versus lower MedDiet adherence 
(95% CI: 0.78 to 0.98, p=0.017, I2=69.6%, Q=41.1, τ2=0.03, df=17).   
Conclusions: Data suggest that MedDiet is an effective dietary strategy to aid BP control, 
which may contribute towards the lower risk of CVD reported with this dietary pattern.  This 
study was registered with PROSPERO: CRD42019125073.   
 




Hypertension is associated with increased risk of ischemic heart disease, stroke, chronic kidney 
disease, and neurodegenerative diseases and is a significant tractable cause of worldwide 
morbidity and mortality [1–3]. Despite substantial advances in the pharmacotherapy of 
hypertension, the global burden of this condition continues to increase.  Indeed, by 2025 it is 
estimated that there will be over 1.6 billion hypertensive individuals worldwide [4].  Identifying 
effective strategies to help control blood pressure (BP) and prevent or treat hypertension, either 
alone or alongside pharmacotherapy, is therefore of paramount importance.  
 
Diet is an effective modulator of BP [5,6] and, given the likely cumulative and synergistic 
effect of individual foods and dietary compounds [7], dietary patterns including the 
Mediterranean diet (MedDiet) may be particularly effective in aiding BP control.  The MedDiet 
emphasises high consumption of fruits and vegetables, legumes, tree nuts, whole grains, fish 
and olive oil.  Fish, poultry and red wine are consumed in moderate amounts, whilst red and 
processed meat consumption is relatively low [8,9]. Numerous observational studies have 
reported reduced risk of hypertension with higher MedDiet adherence [10–13], whilst several 
randomised controlled trials (RCTs) have demonstrated BP lowering effects of MedDiet 
interventions [14–16].  Nevertheless, the reported effects of a MedDiet on BP are inconsistent, 
with several studies reporting minimal or no effect of this dietary pattern [17–20], which could 
be related to differences in study design (e.g. observational studies vs. RCTs, study duration, 
paired vs. independent groups, type of control group) or participant characteristics (e.g. age, 
health status, baseline BP).  
 
Meta-analysis of existing studies could help resolve the ambiguity around the effects of a 
MedDiet on BP, and identify factors that could account for the varying results reported in the 
literature.  Such knowledge could be used to optimise and target future MedDiet interventions 
for BP reduction. To this end, we conducted a systematic review and meta-analysis of RCTs 
investigating the effects of MedDiet interventions on BP, and examined factors that could 
account for the divergent effects reported in the literature.  In addition, we also explored 
associations between MedDiet adherence and risk of hypertension in observational studies.  
Meta-analysis of RCTs allowed us to assess the effects of the MedDiet on BP in controlled 
experimental settings, where studies include a standardised, well-defined intervention with 
strict study inclusion/ exclusion criteria and allow direct cause-effect relationships to be 
established [21,22].  Meanwhile, meta-analysis of observational studies allowed us to explore 
effectiveness of a MedDiet in real-world circumstances where the composition of the diet and 
characteristics of participants may be more variable, yet with larger sample sizes and longer 
follow up than is feasible in most intervention studies [21,22].  Consequently, the inclusion of 
both RCTs and observational studies in this review is complementary [21,22], with each study 
design providing an important piece of information about the potential role of a MedDiet in BP 
control.     
 
METHODS 
The current systematic review and meta-analysis was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [23], and 
was registered with the PROSPERO database (CRD42019125073). 
 
Literature search 
PubMed, The Cochrane Library, and EBSCOhost (including MEDLINE, SPORTDiscus, 
PsycINFO, and CINAHL) were searched from inception through to 21st January 2020 for 
relevant articles. Search terms related to the MedDiet and BP, with MeSH terms utilised where 
appropriate (details of the specific search strategy for each database can be found in 
Supplemental Digital Contents 1). Reference lists of eligible studies and review articles were 
also searched for potentially relevant articles. No publication date or language restrictions were 
applied. To minimise potential publication bias, grey literature was included in search results. 
 
Study selection 
The following criteria were applied to identify articles for inclusion in this systematic review 
and meta-analysis:  
 
General criteria 
1) Both RCTs and observational studies were included.   
2) Only studies with adult participants (aged ≥18 years) were included.  Participant were 
not excluded based on health status or smoking history.  
 
RCTs 
1) No exclusion criteria were made based around the design of the RCT (i.e., cross-over 
or parallel design, intervention duration, blinding, or type of control group) 
2) RCTs which tested the effect of a MedDiet (defined as such by the authors of each 
study) alone or in combination with other lifestyle, clinical or pharmacological 
interventions were included providing the study included a comparable and valid 
control group. For example, if the MedDiet was combined with exercise, the control 





1) No exclusion criteria were made based around the design of observational studies (i.e., 
cross-sectional, case-control, or prospective studies). 
2) Studies reporting associations between MedDiet adherence and odds of hypertension 
were included, providing the MedDiet was compared against a reference or control 
group.  We did not include studies exploring linear associations between MedDiet 
adherence and blood pressure because beta values may not be comparable between 
studies.  
3) No exclusion criteria were applied based on the method used to define MedDiet 
adherence. 
 
Two researchers (OC and NM) independently screened the titles and abstracts of retrieved 
articles to evaluate their eligibility for inclusion in the review and later compared notes to reach 
a consensus.  Disagreements about the eligibility of potential studies were resolved by a third 
reviewer (MS).  Potential studies that could not be excluded based on assessment of title and 
abstract were moved to the full-text stage of the review for further evaluation.  Full-texts of the 
selected articles were appraised critically against the study inclusion/ exclusion criteria by two 
researchers (OC and NM), and a third researcher (MS) helped resolve any disputes.  
 
Data extraction  
Data were extracted by one investigator (AG) and checked for accuracy by a second 
investigator (OMS). The following information was extracted from the eligible articles: author, 
year of publication, study design, study duration, sample size, details of the intervention 
(control and MedDiet), age, sex, ethnicity, BMI, baseline and post-intervention measurements 
of systolic and diastolic BP (RCTs), risk of hypertension (observational studies).  
Assessment of study quality 
Risk of bias of the included studies was evaluated by one investigator (AG) and checked for 
accuracy by a second investigator (OMS).  The Cochrane risk of bias tool [24] was used to 
evaluate RCTs.    Studies were classified as high risk, low risk or, when insufficient detail were 
reported, unknown risk of bias. The Newcastle-Ottowa tool was used to evaluate risk of bias 
in observational studies. Studies were classified as high quality (≥7 stars), medium quality (4-
6 stars) or low quality (0-3 stars) [25]. An adapted version of this tool was used for evaluating 
cross-sectional studies [26]. A third reviewer (MS) resolved any disputes.   
 
Statistical analysis 
Statistical analyses were conducted by KD. A random effects meta-analysis was conducted 
using the metafor package [27] in R version 3.6.3 [28]. For analysis of the effects of MedDiet 
on BP in RCTs, sample size, mean and standard deviation (SD) of BP measurements for 
MedDiet and control groups were extracted and used in the analyses. Standard error of the 
mean (SEM) and confidence intervals (CI) were back-calculated to SD, as required, using 
standard methods [24]. In circumstances in which baseline measurements were not reported, 
the sample size, means and SD of the difference were used. Alternatively, the sample size, 
mean difference and the p value of the difference were used if SD of the difference was not 
available. For observational studies reporting associations between MedDiet adherence and 
risk of hypertension, odds ratios were extracted, alongside information on 95% CI and sample 
size of the population.  Where odds ratios were not provided but studies met the review 
inclusion criteria, odds ratios were calculated using raw counts for the number of participants 
with hypertension.  Additional data were requested from authors where necessary.     
 
Correlations for paired data were determined using standard methods of back-calculation from 
studies where mean, SD, and SD of the difference or exact p-values were presented [18,19,29].  
The mean of these values was used in the calculation of relevant effect sizes, with sensitivity 
analysis performed using the highest and lowest correlation calculated from these studies. The 
correlations for systolic BP were as follows: r=0.39 [29], r=0.61[19], and r=0.71 [18]. The 
correlations for diastolic BP were as follows: r=0.51 [29], r=0.55 [19], and r=0.55 [18]. 
 
For the PREDIMED trial, to avoid duplication of single participants within the meta-analysis, 
data from Casas et al. [16] were used for the main analysis because this has the longest duration 
follow-up of the identified studies. To identify whether the use of alternative PREDIMED 
datasets would have influenced our results, we conducted sensitivity analyses where data were 
substituted in turn for other PREDIMED sub-studies [30,31]. Where studies included 
measurements at multiple time-points, the final study end-point was used for analysis to enable 
the effects of the entire study duration to be considered. 
 
Subgroup analyses were undertaken to investigate the influence of participant characteristics 
(healthy participants vs. high CVD risk participants), study design (paired participants vs. 
independent groups) and control diet (low fat vs. habitual vs. other) for RCTs.  Random effects 
meta-regression was performed to investigate the relationship between changes in BP in 
response to MedDiet interventions and baseline BP, age, BMI, and intervention duration.  
 
Heterogeneity between trials was estimated using restricted maximum likelihood and assessed 
using the I-squared statistic, Tau-squared statistic and the Chi-squared statistic. Case-deletion 
diagnostics were performed to investigate influential studies within each analysis. This 
included determination of externally studentized residuals, DFFITS values, Cook’s distances, 
covariance ratios, estimates of τ2 and estimates of the Q-statistic when each study is removed 
in turn. Sensitivity analyses were performed by repeating the analysis of main effects with 
influential studies removed, to determine whether these studies markedly affected the overall 
conclusions [27].  Small study effects were explored with funnel plots and by quantifying 
Egger’s linear regression intercept. A large and statistically significant Egger’s statistic 




A total of 2025 articles were identified through database screening and other sources, after 
removal of duplicates.  After screening the titles and abstracts, 388 full texts were retrieved for 
further evaluation.  A total of 35 studies were identified as suitable for inclusion in the 
quantitative synthesis, of which 19 were RCTs and 16 were observational studies (Figure 1).  
 
Participant demographics and study characteristics  
RCTs 
The total number of participants across the 19 RCTs was 4137 (Table 1).  The median number 
of participants per study was 144 (range: 12 – 1128), the median participant age was 53.0 
(range: 25.0 – 70.9) years, and the median study duration was 26 (range: 1.4 – 260) weeks.  Of 
the 19 RCTs, 16 were parallel and 3 were crossover study designs.  The majority of studies 
investigated effects of the MedDiet in participants defined as possessing high CVD risk (n=11). 
Studies were also conducted in healthy individuals (n=5), participants with obesity and the 
metabolic syndrome (n=1), liver disease (n=1), and obesity, type II diabetes or coronary heart 
disease (n=1).  Various forms of MedDiet were provided across studies including a MedDiet 
(n = 14), a MedDiet supplemented with olive oil (n = 2), a MedDiet supplemented with nuts (n 
= 1), a MedDiet supplemented with olive oil and nuts (n = 1), a low GI MedDiet (n=1), and a 
MedDiet with energy restriction (n = 1).  In addition, a range of different control treatments 
were employed including a low fat diet (n = 8) [16–18,20,32–35], participants habitual diet 
(n=5) [14,15,36–38], a prudent diet (n=1) [39], a Palaeolithic diet (n=1) [40], a Central 
European diet (n=1) [41], a vegan diet (n=1) [19], a low GI diet (n=1), and an energy-restricted 
low fat diet (n=1) [42].   
 
Observational studies 
The total number of participants from the 16 observational studies was 59,001 (Table 2), and 
the median number of participants per study was 2781 (range: 433 – 14,057).  There were 14 
cross-sectional and 2 prospective studies included in the analysis. Diet was assessed via food 
frequency questionnaires in 14 studies and 24-hour dietary recalls in two studies, one of which 
also involved food weighing.  A range of scores were used to define MedDiet adherence, 
including: the 55-point Panagiotakos MedDietScore (n= 4) [43], 14-point MEDAS score (n=3) 
[44], an adapted 8-point Trichopoulou score (excluding olive oil; n=1) [45], the Modified 9-
point Trichopoulou Score (n=1) [46], a custom 30-point MedDiet score (n=1) [10], a 52-point 
Lebanese MedDiet score (n=1) [47], a 60-point MedTypeDietScore (n=1) [48], a modified 17-
point MedDiet score (n=1) [49], an 11-point Pyramid MedDiet score (n=1) [50], and the MED-
LITE score (n=1) [12].  In addition, one study derived a MedDiet adherence score a posteriori 
via principal component analysis [51].    
 
Effects of MedDiet interventions on systolic BP  
MedDiet intervention reduced systolic BP by mean -1.4 mmHg compared with control (95% 
CI: -2.4 to -0.4 mmHg, p = 0.007, Figure 2). The degree of heterogeneity between studies was 
moderate (I2 = 53.5%, Q = 44.7, τ2 = 1.65, df = 19). Sensitivity analyses revealed that the 
effects of MedDiet interventions on systolic BP remained similar throughout the range of 
correlation coefficients identified for paired comparisons (r=0.39: -1.4 mmHg, 95% CI: -2.5 to 
-0.4 mmHg, p = 0.007; r = 0.71: -1.4 mmHg, 95% CI: -2.5 to -0.4 mmHg, p = 0.008). The 
substitution of datasets from the PREDIMED cohort had a mixed effect on the findings 
(Domenech et al. [31]: -1.6 mmHg decrease, 95% CI: -2.7 to -0.5 mmHg, p = 0.004; Toledo et 
al. [30]: -0.6 mmHg decrease, 95% CI: -1.2 to 0.0 mmHg, p = 0.059). Case-deletion diagnostics 
revealed one influential study for the effect of MedDiet interventions on systolic BP [36] 
(Supplemental Digital Content 2). The influential effect of Itsiopoulos et al. [36] was due 
primarily to the large study weighting of 16.0% combined with a large DFFITS value. 
Between-study heterogeneity reduced substantially when this study was excluded from the 
model. However, the removal of this influential study did not alter the overall estimate of effect 
size (-1.6 mmHg, 95% CI: -2.7 to -0.6 mmHg, p = 0.002). 
 
Meta-regression analysis revealed that longer study duration was associated with greater 
decrease in systolic BP (slope: -0.017 [CI: -0.028 to -0.006] mmHg for each 1 day increase in 
study duration; p = 0.003; Supplemental Digital Content 3). Additionally, higher baseline 
systolic BP was associated with significantly greater reduction in response to MedDiet 
intervention (slope: -0.091 [CI: -0.161 to -0.021] mmHg for each 1 mmHg higher systolic BP 
at baseline; p = 0.011; Supplemental Digital Content 4; n=19). The effect of MedDiet 
interventions on systolic BP was not significantly associated with participant age (p = 0.205; 
n=19) or baseline BMI (p = 0.536; n=18). Subgroup analysis revealed no influence of 
participant health status (healthy vs. high CVD risk; p=0.336), study design (parallel vs. 
crossover; p=0.764) or control diet (low fat vs. habitual vs. other; p=0.801) on the effect of the 
MedDiet interventions on systolic BP.  Inspection of the funnel plot and Egger's regression 
intercept for systolic BP revealed evidence of small study effects (p = 0.007; Supplemental 
Digital Content 5).  
 
Effects of MedDiet interventions on diastolic BP 
MedDiet intervention reduced diastolic BP by mean -1.5 mmHg compared with control (95% 
CI: -2.7 to -0.3 mmHg, p = 0.013, Figure 3). The degree of heterogeneity between studies was 
moderate (I2 = 71.5%, Q = 51.6, τ2 = 4.72, df = 19). Sensitivity analyses revealed that the 
effects of MedDiet intervention on diastolic BP remained similar throughout the range of 
correlation coefficients identified for paired comparisons (r=0.51: -1.5 mmHg , 95% CI: -2.7 
to -0.3 mmHg, p = 0.013; r=0.55: -1.5 mmHg decrease, 95% CI: -2.7 to -0.3mmHg, p = 0.013). 
The substitution of datasets from the PREDIMED cohort did not alter the findings (Domenech 
et al. [31]: -1.1 mmHg, 95% CI: -1.8 to -0.5mmHg, p < 0.001; Toledo et al. [30]: -0.9 mmHg, 
95% CI: -1.4 to -0.5 mmHg, p < 0.001). 
 
Case-deletion diagnostics revealed one influential study for the effect of MedDiet intervention 
on diastolic BP (Casas et al. [16] B; Supplemental Digital Content 6). The influential effect of 
Casas et al. [16] is due to this study being an outlier within the analysis, as demonstrated by 
large changes in model fit with case-deletion, despite average study weighting. However, the 
removal of this influential study did not alter the overall estimate of effect size (-1.2 mmHg 
decrease, 95% CI: -2.1 to -0.2 mmHg, p = 0.019). 
 
Meta-regression analysis revealed that longer study duration was associated with greater 
decrease in diastolic BP (slope: -0.020 [CI: -0.032 to -0.008] mmHg for each 1 day increase in 
study duration; p=0.003; Supplemental Digital Content 7). The effect of MedDiet intervention 
on diastolic BP was not affected by the age (p = 0.260, n=19), BMI (p = 0.453, n=18), baseline 
diastolic BP (p = 0.106, n=19) or health status of participants (healthy vs. high CVD risk; p = 
0.265), nor by the study design (parallel vs. crossover; p = 0.194) or control diet (low fat vs. 
habitual vs. other; p=0.694). Inspection of the funnel plot and Egger's regression intercept for 
diastolic BP revealed little evidence of small study effects for diastolic BP (p = 0.523; 
Supplemental Digital Content 8). 
 
Associations between MedDiet adherence and risk of hypertension 
Meta-analysis of the observational studies demonstrated that higher versus lower MedDiet 
adherence was associated with a mean decrease of 13% in the odds of developing hypertension 
(OR: 0.87 [95% CI: 0.78 to 0.98], p = 0.017, Figure 4). The degree of heterogeneity between 
studies was moderate (I2 = 69.6%, Q = 41.1, τ2 = 0.03, df = 17). Case-deletion diagnostics 
revealed one influential study for the effect of MedDiet adherence on hypertension prevalence 
[52]. The study by Vicinanza et al. [52] was a substantial outlier, as identified by large changes 
in all model fit parameters after removal of this study, and moderate study weighting 
(Supplemental Digital Content 9). However, the removal of this influential study did not alter 
the overall estimate of the OR (OR: 0.94 [95% CI: 0.89 to 0.99], p = 0.035). Subgroup analysis 
demonstrated that the relationship between Mediterranean diet adherence and hypertension 
prevalence did not differ between longitudinal and cross-sectional studies (p = 0.865). 
Inspection of the funnel plot and Egger's regression intercept for hypertension prevalence 
revealed evidence of small study effects (p = 0.003; Supplemental Digital Content 10). 
 
Study quality and risk of bias  
Overall, the quality of RCTs included in this meta-analysis was mixed (Supplemental Digital 
Content 11 and 12).  There was a low risk of attrition bias in all included studies but over 25% 
of RCTs showed high risk of selection bias, performance bias and detection bias.  Likewise, in 
over 25% of RCTs, insufficient information was provided to assess the risk of selection bias, 
performance bias and reporting bias.  Of the two prospective studies included in this review, 
one had a moderate quality score of 6 [11] and one had a high quality score of 7 [53] 
(Supplemental Digital Content 13). Twelve of the cross-sectional studies had moderate quality 
scores of 4-6 [10,12,13,47,48,50,51,54–57] whilst two cross-sectional studies had low quality 
scores of 2 [52,58] (Supplemental Digital Content 14).   
 
DISCUSSION 
The results of this systematic review and meta-analysis demonstrate that intervention with a 
MedDiet reduces systolic and diastolic BP by mean -1.4 mmHg and -1.5 mmHg, respectively.  
Meta-regression analysis revealed that longer study duration was associated with greater 
decreases in both systolic and diastolic BP.  Furthermore, higher baseline BP was associated 
with significantly greater reductions in systolic, but not in diastolic, BP in response to a 
MedDiet.  Further supporting evidence for a beneficial role of the MedDiet for BP control 
under real world conditions was provided by analysing data from observation studies, which 
showed an overall 13 % reduction in the risk of hypertension with higher versus lower 
adherence to the MedDiet.    
 
The results of this study are broadly consistent with the findings of three meta-analyses 
published in 2016, which reported overall reduction in systolic BP of -1.1 to -3 mmHg and 
diastolic BP of -0.7 to -2 mmHg following MedDiet intervention  [59–61]. However, crucially, 
our findings are based on the analysis of 19 RCTs compared with only 3-6 studies in these 
earlier reviews, which adds confidence to our results. The effects of MedDiet interventions on 
BP were also explored in a more recent network meta-analysis by Schwingshackl and 
colleagues [62], who contrasted the BP lowering effects of different dietary patterns, 
administered for 12 or more weeks, to individuals with elevated BP.  Compared with a low-fat 
diet, the MedDiet reduced systolic and diastolic BP by mean -1.7 and -1.5 mmHg, respectively 
– findings similar to those of the current study.  Interestingly, Schwingshackl and colleagues 
identified the MedDiet as the 3rd most effective dietary pattern for reducing diastolic BP after 
the Dietary Approach to Stop Hypertension (DASH) and the Palaeolithic diet – both of which, 
like the MedDiet, are rich in plant-based foods [62]. Since these findings were based on indirect 
comparisons of the efficacy of these dietary patterns, which weakens the conclusions to be 
drawn compared with the synthesis of direct evidence [63], future RCTs that compare the 
efficacy, and also the acceptability, of these dietary patterns for BP reduction would be valuable 
in informing future public health guidelines and interventions.  Finally, effects of the MedDiet 
on BP were evaluated as part of a recent Cochrane Review exploring the effectiveness of a 
MedDiet in primary and secondary prevention of CVD [64].  In that study, MedDiet 
interventions significantly reduced systolic (-2.9 mmHg) and diastolic (-2.0 mmHg) BP in 
primary prevention settings when compared against minimal to no intervention.  Conversely, 
effects in other settings were not significantly different to control [64].  This study did not 
explore overall effects of a MedDiet on BP, instead focusing on small sub-group analyses 
including 1-4 studies where participants were split by CVD status (primary or secondary 
prevention) and type of control group (minimal vs alternative dietary intervention), which 
limits the statistical power to detect an effect.  Moreover, as that study only included 
interventions with minimum 3 months duration, the effects of shorter MedDiet interventions 
could not be determined [64].  Therefore, overall, our study provides new information on the 
potential role of a MedDiet for BP control and builds upon the findings of previous research.   
 
Although the BP lowering effects of a MedDiet observed here are quantitatively small, on a 
population level, such small reductions in BP are likely to be important.  Indeed, a -2 mmHg 
reduction in systolic BP has been estimated to decrease the risk of death from stroke by 10 % 
and from ischemic heart disease by 7 % [65]. The MedDiet may also reduce CVD risk via 
multiple other mechanisms [66–69], such that the overall cardioprotective benefits of this 
dietary pattern are likely to be much greater. Therefore, a MedDiet could be recommended as 
part of public health guidelines to reduce population risk of hypertension and CVD.  To this 
end, meta-regression analysis revealed two novel findings which may be useful in the design 
of future intervention studies or public health guidelines for BP reduction. Firstly, we found a 
positive association between study duration and the magnitude of reduction in both systolic 
and diastolic BP following a MedDiet, suggesting that longer term consumption of this dietary 
pattern may maximise BP lowering effects.  These findings echo those from our recent meta-
analysis in which we observed a similar positive association between the duration of MedDiet 
intervention and effects on measures of endothelial function such as flow mediated dilation 
[66].  Secondly, we observed greater reductions in systolic BP in individuals with higher 
baseline systolic BP values, indicating that these individuals are an important population target 
for future MedDiet interventions for BP reduction.   
 
Strengths and limitations 
The current study has several strengths.  Firstly, we undertook a number of sensitivity analyses 
which demonstrated the robustness of our findings.  These included exploring whether 
substitution of other PREDIMED datasets would influence the results of our analyses, thus 
overcoming the potential consequences of arbitrary decisions made in selecting the ‘best’ 
dataset for inclusion from this large-scale RCT.  In addition, by undertaking sub-group and 
meta-regression analyses, we have provided novel information on factors that moderate the 
BP-lowering effects of the MedDiet, including intervention duration and baseline BP.  
Interestingly, recent data from the NuAge trial suggests that the BP lowering effects of a 
MedDiet are also moderated by medication status [15].  Specifically, individuals taking anti-
hypertensive medication experienced a less pronounced reduction in BP with consumption of 
a MedDiet compared with individuals not taking anti-hypertensives, which could be due to 
overlapping mechanisms of action or a reduced capacity to further lower BP with diet when 
accounting for the effects of the medication. Given the nature of our analysis, it was not 
possible to explore the modulating impact of anti-hypertensive medication use on BP lowering 
effects of the MedDiet, which is acknowledged as a limitation of this analysis and warrants 
further research. In a similar manner, we were unable to identify whether weight loss 
contributed towards the BP lowering effects of a MedDiet in this analysis given insufficient 
data available on change in BMI/ body weight in published studies. Nevertheless, a MedDiet 
without weight change has been shown to elicit BP lowering effects, suggesting that weight 
loss is not essential to reduce BP with consumption of this dietary pattern [16].   A further 
limitation of this meta-analysis is the quality of included studies, which was mixed.  Most of 
the observational studies included in this review were cross-sectional, for which there is a 
greater risk of reverse causality compared with prospective studies.  Nevertheless, we found 
no difference in the results between cross-sectional and prospective trials, suggesting that our 
findings were not influenced by this factor.   
 
Conclusions and future directions 
The results from this meta-analysis suggest that the MedDiet is an effective dietary strategy to 
reduce BP and to decrease risk of hypertension, which may contribute towards the lower CVD 
risk reported with this dietary pattern.  Our findings that the MedDiet is increasingly effective 
when consumed over a prolonged period and when administered to individuals with elevated 
baseline BP may help inform public health guidelines and the design of future RCTs.   
 
A number of questions regarding effects of the MedDiet on BP remain unanswered, and could 
be explored in future research.  Firstly, further studies are needed to established whether 
particular MedDiet components may be driving the BP lowering effects of this dietary pattern.  
It has been suggested that the low sodium content of the MedDiet may play a key role in its BP 
lowering effects [12].  However, it is also possible that the high content of nitrate-rich 
vegetables [67] – which have been shown to lower BP by up to 10 mmHg in several RCTs [70–
72] -  fish [73], or other foods or bioactives, could be key. Better understanding of the ‘active’ 
components of this diet could be valuable for further refining dietary recommendations for BP 
reduction.  Additional research to identify groups of individuals who may be particularly 
receptive to the BP lowering effects of a MedDiet is also warranted to help develop targeted 
nutritional interventions [74].  Most studies to date have evaluated BP in a clinical setting, and 
additional research exploring effects of the MedDiet on 24 hour ambulatory BP is warranted, 
which is superior to clinic BP in predicting cardiovascular outcomes [75]. Furthermore, 
additional prospective cohort studies are warranted to explore longitudinal associations 
between MedDiet adherence and risk of hypertension, given most observational studies to date 
are cross-sectional.  Such studies should include large sample sizes with diverse participant 
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Figure legends 
Figure 1. Flow diagram of the selection process of studies included in this meta-analysis 
 
Figure 2.  Forest plot of the effects of a MedDiet on systolic BP in RCTs 
 
Figure 3.  Forest plot of the effects of a MedDiet on diastolic BP in RCTs 
 
Figure 4.  Forest plot of the associations between MedDiet adherence and risk of hypertension 
in observational studies  
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Table 1. Summary of baseline data reported in randomised controlled trials investigating effects of the Mediterranean diet on blood pressure 










Type of intervention Type of 
control 
Assaf-Balut 
et al. (2019) 
Parallel High CVD risk 697 0  MedDiet: 33.0 
Control: 32.5  
MedDiet: 23.2  
Control: 23.7  
 
24-26  MedDiet + EVOO  
+ nuts 
Low fat diet 
Bajerska et 
al. (2018)  
Parallel Obesity + MS 
 
144 0  -  -  16  MedDiet Central 
European diet 
 
Casas et al. 
(2016) 
Parallel High CVD risk 160 74  MedDiet + 
EVOO: 66.7  
MedDiet + 
nuts: 65.8 
Control: 66.3  
MedDiet + 





260 MedDiet + EVOO 
MedDiet + nuts 
Low fat diet 
Ceriello et 
al. (2014) 
Parallel High CVD risk 24 17  -  MedDiet: 29.8  
Control: 29.2 
 
13  MedDiet + EVOO Low fat diet 
Davis et al. 
(2017) 
Parallel Healthy 149 84  MedDiet: 71.0  
Control: 70.9  
 
MedDiet: 26.7  
Control: 27.1  
 
26  MedDiet Habitual diet 
de Lorgeril 
et al. (1994) 
Parallel High CVD risk 605 550  MedDiet: 53.5 
Control: 53.5  
 
MedDiet: 25.8  
Control: 25.8  
104  MedDiet Habitual diet 
Esposito et 
al. (2004) 
Parallel High CVD risk 180 99  MedDiet: 44.3  
Control: 43.5 
MedDiet: 27.9  
Control: 28.1  
 
104  MedDiet Prudent diet 
Itsiopoulos 
et al. (2011) 
 
Crossover High CVD risk 27 16  59  
 
30.7  13  MedDiet Habitual diet 
Jennings et 
al. (2019) 
Parallel Healthy 1128 503  MedDiet: 70.7  
Control: 71.0 
MedDiet: 26.7  
Control: 26.6  
 
52  MedDiet Habitual diet 
Jospe et al. 
(2020)* 
Parallel Healthy 114 34 MedDiet: 44.2 
Control: 42.6  




52  MedDiet Paleo diet 
Lee et al. 
(2015) 




Parallel High CVD risk 215 106  MedDiet: 52.4  
Control: 51.9 
MedDiet: 29.7  
Control: 29.5  
 
208  MedDiet Low fat diet 
Osella et al. 
(2018)* 
Parallel High CVD risk 100 57  MedDiet: 58.4  
Control: 57.5 
 
-  26  Low GI MedDiet Low GI diet 
Properzi et 
al. (2018) 
Parallel Liver disease 51 26  MedDiet: 51.0  
Control: 53.0 
MedDiet: 31.5 
Control: 30.2  
 
12  MedDiet Low fat diet 
Rogerson et 
al. (2018) 
Parallel Healthy 24 6  MedDiet: 25.0  
Control: 26.0 
 
MedDiet: 23.1  
Control: 25.1 
4  MedDiet Vegan diet 
Ryan et al. 
(2013) 
Crossover High CVD risk 12 6  55.0  32.0  6  
 
MedDiet Low fat 
 
 
Shai et al. 
(2008)* 
Parallel Obese/ T2DM/ 
/CHD 
213 178  MedDiet: 53.0  
Control: 51.0  
MedDiet: 31.2  
Control: 30.6  
 
104  MedDiet (restricted 
calories) 




Tuttle et al. 
(2008) 
 
Parallel High CVD risk 101 75  MedDiet: 58.0  
Control: 58.0  
MedDiet: 30.0  
Control: 31.0  
104  MedDiet Low fat diet 
Vincent-
Baudry et al. 
(2005) 
Parallel High CVD risk 169 69  MedDiet: 50.8  
Control: 51.6  
MedDiet: 28.7  
Control: 28.7  
12  MedDiet Low fat diet 
MedDiet = Mediterranean diet; EVOO = Extra Virgin Olive Oil; CVD = Cardiovascular Disease; MS = Metabolic Syndrome; T2DM = Type II Diabetes. *Values presented 
for groups used in the statistical analysis only.   
Table 2. Summary of observational studies investigating associations between Mediterranean diet adherence and risk of hypertension  
Author Study design  
(follow up duration) 
Sample 
size 








Alvarez et al. 
(2006) 
 
Cross-sectional 578 249  >18  -  FFQ Custom 30-point 
MedDiet score 
Alvarez-Alvarez 
et al. (2019) 
 
Cross sectional 6620 3427  64.8 32.3 FFQ 14-point MEDAS 
Score 
Cherfan et al. 
(2018) 
 











Foscolou et al. 
(2016) 
 
Cross-sectional 724 315  74.0  29.0  FFQ 55-point 
MedDietScore 
Georgousopoulou 
et al. (2017) 
 
Cross-sectional 2749 1369  74.5 28.4 FFQ 55-point 
MedDietScore 
Grosso et al. 
(2014) 
 
Cross-sectional 3090 1295  51.7  25.4  FFQ 55-point 
MedDietScore 
Grosso et al. 
(2015) 
 
Cross-sectional 8821 4291  -  28.1 FFQ 60-point 
MedTypeDietScore 
Heindel et al. 
(2019) 
 
Cross-sectional 2813 1651  60.1  28.8  FFQ Modified 9-point 
Trichopoulou 
Score  




5324 0  52.4  24.9 FFQ Modified 17-point 
MedDiet score 
(minus olive oil) 
Kanauchi et al. 
(2015) 
 
Cross-sectional 433 433  45.3  24.8 FFQ 11-point Pyramid 
Score 
Karageorgou et al. 
(2019) 
 





La Verde et al. 
(2017) 
 




Cross-sectional 3204 1380  67.2 29.9 FFQ 14-point MEDAS 
Tyrovolas et al. 
(2014) 
 
Cross-sectional 2732 1352  73.9 28.4 FFQ 55-point 
MedDietScore 
Vicinanza et al. 
(2017)  
Cross-sectional 476 202  70.4  26.7 FFQ 14-point MEDAS 
MedDiet = Mediterranean diet; FFQ = Food Frequency Questionnaire.  
 
 












Figure 2.  Forest plot of the effects of a MedDiet on systolic BP in RCTs 
  
 
Figure 3.  Forest plot of the effects of a MedDiet on diastolic BP in RCTs 
  
 
Figure 4.  Forest plot of the associations between MedDiet adherence and risk of hypertension 
in observational studies  
 
